Zacks Research Upgrades Bruker (NASDAQ:BRKR) to “Strong-Buy”

Bruker (NASDAQ:BRKR) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

Several other equities research analysts also recently issued reports on BRKR. TD Cowen restated a “hold” rating on shares of Bruker in a report on Wednesday, July 15th. Wolfe Research assumed coverage on Bruker in a research note on Monday, June 1st. They set a “peer perform” rating for the company. Guggenheim raised their price target on shares of Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Weiss Ratings upgraded shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, June 3rd. Finally, Stifel Nicolaus set a $50.00 price target on shares of Bruker in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $56.64.

Bruker Stock Up 4.3%

Shares of Bruker stock opened at $52.47 on Tuesday. Bruker has a 1-year low of $28.53 and a 1-year high of $65.30. The company has a market capitalization of $7.99 billion, a PE ratio of -74.96, a P/E/G ratio of 1.61 and a beta of 1.28. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.72. The business has a 50-day moving average of $58.67 and a 200-day moving average of $46.73.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.38 by $0.11. The business had revenue of $838.50 million for the quarter, compared to analysts’ expectations of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The company’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities analysts forecast that Bruker will post 2.12 EPS for the current fiscal year.

Institutional Trading of Bruker

Large investors have recently modified their holdings of the company. Los Angeles Capital Management LLC acquired a new position in Bruker during the 4th quarter valued at about $26,000. Parallel Advisors LLC raised its holdings in shares of Bruker by 121.0% during the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after buying an additional 479 shares during the last quarter. Allworth Financial LP boosted its position in shares of Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after buying an additional 257 shares during the period. Essential Partners LLC bought a new position in Bruker in the 1st quarter worth approximately $36,000. Finally, FNY Investment Advisers LLC acquired a new stake in Bruker in the 2nd quarter valued at approximately $60,000. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker News Roundup

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Bruker reported second-quarter adjusted EPS of $0.49, above the $0.38 analyst consensus and up from $0.32 a year earlier. Revenue increased 5.2% year over year to $838.5 million. Bruker Q2 Earnings Beat Estimates
• Positive Sentiment: Zacks Research upgraded BRKR from “hold” to “strong buy,” providing a positive counterpoint to the broader analyst reaction. Zacks.com
• Positive Sentiment: Management highlighted margin strength on the earnings call, while maintaining fiscal 2026 adjusted EPS guidance of $2.10 to $2.15, broadly in line with the $2.12 consensus. Bruker Earnings Call Highlights Margin Strength

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.